RenovoRx Inc(RNXT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:10 AM ET (Korea 10/27 17:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.31 | Insider Own | 3.66% | Shs Outstand | 45.1M | Perf Week | 12.93% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 46.67% | Insider Trans | 1.54% | Shs Float | 43.5M | Perf Month | -21.08% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.06 | Inst Own | 20.58% | Short Float | 2.18% | Perf Quarter | 44.38% |
| Income | -0.01B | P/S | 29.86 | EPS this Y | 17.97% | Inst Trans | -0.15% | Short Ratio | 1.17 | Perf Half Y | 50.56% |
| Sales | 0.00B | P/B | 6.58 | EPS next 5Y | - | ROA | -97.83% | Short Interest | 0.95M | Perf YTD | 55.93% |
| Book/sh | 0.2 | P/C | 6.24 | EPS past 3/5Y | 33.86% 6.34% | ROE | -125.23% | 52W High | -49.42% ($2.59) | Perf Year | 11.02% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | - | ROIC | -132.98% | 52W Low | 86.98% ($0.70) | Perf 3Y | 28.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.29% | Gross Margin | 84.41% | Volatility(W/M) | 6.29% 7.56% | Perf 5Y | -76.35% |
| Dividend TTM | - | EV/Sales | 25.27 | Sales Y/Y TTM | 198.49% | Oper. Margin | -685.22% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.53 | EPS Q/Q | 22.22% | Profit Margin | -621.71% | RSI (14) | 45.9 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.74 | Sales Q/Q | 115.4% | SMA20 | -0.8% ($1.32) | Beta | 1.11 | Target Price | $7.12 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/11/5 | SMA50 | -15.33% ($1.55) | Rel Volume | 0.23 | Prev Close | $1.29 |
| Employees | 17 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 17.24% 29.16% | SMA200 | 19.53% ($1.1) | Avg Volume(3M) | 0.81M | Price | $1.31 |
| IPO | 2021/8/26 | Option/Short | No/Yes | Trades | 568 | Volume | 182,309 | Change | 1.55% |
A clinical-stage biotech developing the RenovoCath technology, which delivers chemotherapy directly into the tumor-feeding artery for the treatment of pancreatic cancer. In a Phase 3 trial, the technology demonstrated an 8-month delay in cancer progression, and it has also received FDA Orphan Drug Designation. Final data is expected in 2027.
Over the past 1 year, roughly in the middle
49% below its 1-year high.
Traded less than usual. That is 23% of its average volume.
Next earnings report: November 5
9 days to go.
RNXT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +18.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,986. Peers typically go for $951.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -76.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 20.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #396 of 594 in the industry
Based on market cap of $59M.
FAQ
What kind of company is RNXT?
RNXT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RNXT?
The market cap of RNXT is approximately $59M, ranking 4,753 within its sector.
What is the 52-week high and low for RNXT?
RNXT has recorded a 52-week high of $2.59 and a low of $0.70.
